300573.SZ
Strong BuyUnloved QualityAI neutralShenyang Xingqi Pharmaceutical Co.,Ltd. · Healthcare · China · $1.9B cap · $22.4M/day traded
CNY 34.68 +2.7% · close 3 Nov · scored 4 Nov
Unloved Quality: Strong and cheap, but the market has not warmed to it.
As of 4 Nov 2026, MoatMap's StockRank for Shenyang Xingqi Pharmaceutical Co.,Ltd. (300573.SZ) is 87/100, ranked against 24,000+ stocks in 35 markets (Quality 90, Value 54, Momentum 42, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
Shenyang Xingqi Pharmaceutical is a Chinese ophthalmic drug maker whose low-dose atropine eye drops for childhood myopia have driven rapid growth, and it scores highly on quality while buying back about 1.1% of its shares over 90 days. Demand for myopia control in China is real and visible. Current intelligence on sales trends, competition from new atropine entrants and pricing policy is thin, so the durability of growth is hard to judge.
ABOUT SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.
Read
Shenyang Xingqi Pharmaceutical Co., Ltd. specializes in the research, development, and manufacture of ophthalmic drugs, including eye drops, gels, and ointments. The company holds a dominant niche position in China's eye care market, driven by its highly successful low-concentration atropine eye drops for slowing myopia progression in children. It operates with high regulatory barriers and strong brand loyalty among ophthalmologists and patients.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.5B | 1.9B | 2.5B | 25.5% | 2.8B |
| EPS (CNY) | 0.61 | 0.68 | 0.95 | 1.95 | 47.7% | 2.24 |
| Shares | 352.3M | 354.1M | 355.8M | 357.3M | +1.4% | 354.9M |
| Debt | 13.8M | 79.1M | 215.3M | 82.0M | 81.1% | 105.7M |
| Equity | 1.6B | 1.7B | 1.6B | 2.0B | 8.4% | — |
| Op CF | 286.3M | 317.6M | 417.0M | 753.4M | 38.1% | 892.3M |
| Inv CF | -299.2M | -261.9M | -215.7M | -269.7M | — | — |
| Fin CF | -158.4M | -84.2M | -318.8M | -458.4M | — | — |
Made a new 52-week low 4 trading days ago, 39% below its 52-week high. The fall has not stopped yet.
Calmer than 62% of stocks we rank over the past year (volatility 36% a year).
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300573.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 300573.SZ | Shenyang Xingqi Pharmaceutical Co.,Ltd.(you) | $1.9B | 87 | Strong Buy |
| 1066.HK | Shandong Weigao Group Medical Polymer Company Limited | $1.8B | 87 | Strong Buy |
| 6699.HK | Angelalign Technology Inc. | $1.8B | 85 | Strong Buy |
| 300888.SZ | Winner Medical Co., Ltd. | $2.7B | 82 | Strong Buy |
| 688029.SS | Micro-Tech (Nanjing) Co.,Ltd | $2.4B | 69 | Buy |
| 300595.SZ | Autek China Inc. | $1.4B | 67 | Buy |
| 300171.SZ | Tofflon Science and Technology Group Co., Ltd. | $1.6B | 60 | Hold |
| 1501.HK | Shanghai INT Medical Instruments Co., Ltd. | $1.1B | 66 | Buy |
| 300358.SZ | Truking Technology Limited | $919M | 68 | Buy |
| 301101.SZ | Mingyue Optical Lens Co.,Ltd. | $1.1B | 61 | Hold |
Peer medians: ROE 4.0% · P/E 26.4x · Gross margin 53.1%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.